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Abstract
Background Late-onset noninfectious pulmonary compli-
cations (LONIPCs) are life-threatening complications of
bone marrow transplantation (BMT). Several pathological
patterns are described in the literature with different
prognoses, and with different relationships to graft-versus-
host disease (GVHD). The role of high-resolution CT
(HRCT) is not yet well established.
Objective To illustrate different patterns of LONIPCs on
HRCT in allogeneic versus autologous BMT in order to
investigate the correlation with chronic GVHD (cGVHD).
Materials and methods A total of 67 HRCT scans were
performed in 24 patients with noninfectious pulmonary
disease at least 3 months after BMT (16 allogeneic,
8 autologous). Abnormality patterns and extension on
HRCT images were correlated with the clinical outcome
and with the severity of cGVHD.
Results Of 24 patients, 9 showed LONIPCs (1 autologous,
8 allogeneic). There was a significant association between
abnormalities on HRCT and severe cGVHD (P=0.038),
with no specific pattern. Prognosis seemed to be related to
the severity of cGVHD and not to the extent of abnormal-
ities on HRCT.
Conclusion The significant association between abnormal-
ities on HRCT and severe GVHD suggests that LONIPCs
can be a pulmonary manifestation of the disease. HRCT is a
useful tool when combined with clinical data.
Keywords HRCT. Graft-versus-host disease .
Late-onset noninfectious pulmonary complications .
Bone marrow transplantation . Children
Introduction
Pulmonary complications after bone marrow transplantation
(BMT) occur in 25% of children [1], and are responsible for
decreased survival time and increased mortality. There has
been a decrease in infectious complications due to the
widespread use of infection prophylaxis, and noninfectious
complications are now the major pulmonary cause of
morbidity and mortality in patients after BMT [2]. In
particular, late-onset noninfectious pulmonary complica-
tions (LONIPCs) occurring beyond 3 months after BMT
have now become recognized as life-threatening complica-
tions. The presence of graft-versus-host disease (GVHD)
seems to be a contributing factor to the advent of non-
infectious pulmonary complications [3]. Furthermore, in
children, the occurrence of severe GVHD increases the
relative risk of developing pulmonary complications by a
factor of two [1]. Diagnosis is crucial since the only
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available treatment for many noninfectious conditions is
increased immunosuppression [4].
While pulmonary histological confirmation is not always
available and bronchoalveolar lavage (BAL) cytology is
generally performed in BMT patients to differentiate
infectious from noninfectious processes, high-resolution
CT (HRCT) is usually a complementary tool, although its
specific role in the diagnosis of LONIPCs is not well
defined. The pathological spectrum of LONIPCs is still
undefined. Palmas et al. [4] proposed that the classification
include bronchiolitis obliterans (BO), BO with organizing
pneumonia (BOOP), diffuse alveolar damage (DAD),
lymphocytic interstitial pneumonia, and nonclassifiable
interstitial pneumonia. Afessa et al. [5] categorized
LONIPCs as BO, BOOP, and idiopathic pneumonia
syndrome. Data in the literature on prognostic significance
and the relationship between different pathological spectra
and chronic GVHD (cGVHD) are scarce and contradictory,
especially in children. Some authors [6, 7] consider BO as
the end-stage damage of pulmonary GVHD, preceded by
BOOP and idiopathic pneumonia syndrome; others consid-
er subclassifications of LONIPCs as separate entities with
different clinical outcomes and different relationships to
GVHD.
The aim of this longitudinal study was to compare HRCT
findings between paediatric allogeneic BMT patients present-
ing with respiratory complications and oncology patients with
similar clinical symptoms but receiving autologous BMT. We
sought to determine whether specific HRCT patterns corre-
lated with the presence of extrapulmonary GVHD in
allogeneic BMT patients with different clinical outcomes,
and could therefore be helpful for diagnostic purposes and
therapeutic interventions.
Materials and methods
Patients
All patients from a paediatric tertiary care teaching hospital
presenting with noninfectious respiratory complications at
least 3 months after allogeneic and autologous BMT were
Table 1 Clinical details for 24
children at least 3 months
after allogeneic or autologous
BMT.
Characteristic Autologous BMT Allogeneic BMT Total
No. of children 8 (33%) 16 (67%) 24 (100%)
Boys 3 11 14
Girls 5 5 10
Age at BMT (years)
Mean 10 9.2 9.3
Range 3.1–15.3 0.3–17 0.3–17
Diagnosis
Neuroblastoma 2 –
Ewing sarcoma 2 –
Rhabdomyosarcoma 1 –
Primitive neuroectodermal tumour 1 –
Acute lymphoblastic leukaemia 1 6
Medulloblastoma 1 –
Acute myelogenous leukaemia – 3
Aplastic anaemia – 2
Chronic myeloid leukaemia – 1
Juvenile myelogenous leukaemia – 1
Fanconi anaemia – 1
Severe combined immune deficiency – 1
Drepanocytosis – 1
BMT ×2 1 (13%) 4 (25%) 5 (21%)
cGVHD 9 (56%)
Grade I/II – 5 (31%)
Grade III/IV – 4 (25%)
Donor type
Related – 6 (38%)
Nonrelated – 10 (63%)
Years between diagnosis and BMT (range) 1.5 (0.5–3) 1.7 (0.2–7) 1.6 (0.2–7)
No. of HRCT scans 24 (35.8%) 43 (64.2%) 67 (100%)
No. of deaths during the study 3 (37.5%) 5 (31.3%) 8 (33%)
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included in the study. To exclude infection, BAL, trans-
bronchial lung biopsy or open lung biopsy was performed;
standard culture and staining methods for bacterial, viral,
and protozoan pathogens were employed.
Patients were identified by reviewing all the medical
charts of patients who had undergone a BMT between
January 2001 and January 2007. Clinical characteristics
were obtained from medical charts and all laboratory results
from electronic patient files. The following data are
reported for each patient group: age, BMT type (allogeneic
or autologous), donor type (related or nonrelated), condi-
tioning regimen, methotrexate dose, use of cyclosporine A,
stage of the underlying disease (first remission or advanced
disease at the time of transplantation), number of BMTs per
patient, clinical outcome, and the presence of GVHD in
allogeneic BMT. In allogeneic BMT patients, clinical
manifestations of GVHD were scored as previously
described by Przepiorka et al. [8]
Respiratory complications were defined as symptoms
such as cough, dyspnoea, hypoxaemia, haemoptysis or
unexplained fever with respiratory symptoms, or persistent
infiltrates on chest radiographs.
HRCT
HRCT (Somatom Sensation 40/64, Siemens, Erlangen,
Germany; MX 8000, Philips, Best, The Netherlands) was
performed at end inspiration using 1-mm collimation at 5-
or 10-mm intervals, 90–120 mAs and 100–120 kVp. Two
paediatric radiologists analysed the HRCT scans and
reached final decisions by consensus with regard to the
spatial extent of the lesions (considered as limited when no
more than one lung segment was involved), and pattern of
abnormality (ground-glass and air-space opacities, bronchi-
al dilatation, bronchial wall thickening, tree-in-bud opaci-
ties, reticular opacities, large or small nodules, mosaic
attenuation, perfusion). Criteria for these findings were
those defined in the Fleischner Society’s glossary of terms
[9].
Once a patient was identified as having LONIPCs, we
attempted to further classify the disease on the basis of
clinical and radiological findings, routine pulmonary
function tests when possible, and pathological findings
when available, according to Afessa et al. [5], as BO,
BOOP, interstitial pneumonia and DAD. In the literature,
patients have been classified as having BO if they show a
decline in FEV1 (forced expired volume in 1 s) of less than
80% of the predicted value and FEV1/FVC (forced volume
capacity) of less than 70% [10]. However, in young
chronically ill children, pulmonary function tests are often
not applicable and seldom performed [11]. Signs of BO on
HRCT are low- or high-attenuation areas, bronchial
dilatation, bronchial thickening, vascular attenuation and Ta
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expiratory air trapping [12]. Bullae or pneumothorax are
considered consequences of obstructive lung disease [13].
Histologically, BO is recognized by intraluminal fibrosis
[14]. Idiopathic pneumonia syndrome is diagnosed if a
patient shows bilateral diffuse parenchymal interstitial/
alveolar infiltrates on chest radiographs and/or CT images
with associated hypoxaemia (PaO2 <70 mmHg, A-aDO2
>20 mmHg) [15].
The diagnosis of DAD requires fulfilment of the
following criteria: diffuse bilateral pulmonary infiltrates,
progressively haemorrhagic BAL fluid from at least three
separate lobes and haemosiderin-laden macrophages on
microscopic examination of the BAL fluid, no improve-
ment with correction of underlying coagulopathy, and/or
fluid overload and no evidence of cardiogenic pulmonary
oedema [4, 16]. BOOP is diagnosed on the basis of the
chest radiographic appearance of patchy air-space opacity,
foci of air-space consolidation and ground-glass opacity on
HRCT images [17–19]. Pathologically, BOOP is character-
Fig. 2 Allogeneic BMT
patients with severe cGVHD
and poor outcome. HRCT
images shows limited alteration
with bullae (a, b arrows), or
extensive abnormalities and
pneumothorax (c arrowheads)
Fig. 1 A 10-year-old child with autologous BMT and good outcome.
Interstitial thickening (arrow) was correlated with the area of
therapeutic radiation
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ized by granulation tissue within the bronchiolar lumen that
proliferates and involves adjacent alveoli [20].
Statistics
SPSS 11.0 statistical software was used for all calculations.
Fisher’s exact test was used to compare categorical
variables. Statistical significance was set as P≤0.05.
Categorical variables compared were: diagnosis of
LONIPCs in allogeneic and autologous BMT recipients
versus presence of GVHD stratified according to grade (I/II
or III/IV), number of BMTs, total body irradiation (TBI,
only in patients after allogeneic BMT) and overall survival
of patients with LONIPCs and GVHD.
Results
Study patients
The review of the medical charts identified 27 patients (14
boys) who had undergone BMT between January 2001 and
January 2007. Three patients died in the days following the
BMT and were excluded from the study. The clinical details
for 24 children surviving at least 3 months after allogeneic
or autologous BMT are summarized in Table 1.
Of the 24 patients, 16 underwent allogeneic BMT (6 had
related donor BMT and 10 had nonrelated donor BMT) and 4
of these 16 underwent BMT twice. The mean age of the
allogeneic BMT patients at the time of transplantation was
9.2 years (range 4.5 months to 17 years) and the mean time
between diagnosis and BMT was 1.7 years (range 0.2–
7 years). Over the same time period, eight patients underwent
autologous BMTand one had two BMTs. Their mean age was
10 years (range 3.1–15.3 years) and the mean time between
diagnosis and BMTwas 1.5 years (range 0.5–3 years).
The conditioning regimen included chemotherapy and
TBI at a total dose of 12 Gy in eight patients (all allogeneic
BMT), chemotherapy and cranial irradiation in one patient
(allogeneic BMT) and chemotherapy alone in 15 patients (7
allogeneic and 8 autologous BMT). Autologous BMT
patients did not receive TBI, but some had radiotherapy
for their underlying pathology before the transplantation.
Mean methotrexate dose was not significantly different
between allogeneic and autologous BMT patients
(1,363 mg/m2 and 2,047 mg/m2, respectively; P=NS).
Cyclosporine A was uniformly started at a dose of 3 mg/kg
Fig. 4 Allogeneic BMT patients with no clinical cGVHD and good
outcome. Extensive involvement of the lung parenchyma with
consolidation (a), ground-glass opacity (b arrow) and nodules (b
arrowhead) and pleural effusion (a, b). The final diagnosis was BOOP
Fig. 3 An 8-month-old patient with allogeneic BMT, severe GVHD
and poor outcome. HRCT image shows diffuse extensive involvement
of the lung parenchyma with ground-glass opacity, consolidation and
interstitial thickening. The diagnosis after BAL was DAD
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per day intravenously on day 1, and then was adjusted
according to blood levels. The overall characteristics of the
two groups of patients were similar.
Of the 16 patients, 12 presented with respiratory
symptoms or chest radiographic anomalies at least 3 months
after allogeneic BMT and underwent 43 HRCT scans, and
8 of the 16 patients (50%) had HRCT evidence of
LONIPCs. All of the eight autologous BMT patients had
HRCT scans (24 HRCT scans in total) on follow-up of the
underlying diseases. One of the eight (12.5%) had HRCT
evidence of LONIPCs. Thus the overall percentage of
LONIPCs in our patients was of 37.5%. In the group of
children who had two BMTs (4 allogeneic and 1 autolo-
gous), 3 developed LONIPCs, while of the 19 patients who
underwent only one BMT, 5 had LONIPCs.
Of the 16 patients, 7 did not develop GVHD; 2 had
LONIPCs. Five patients had mild GVHD (stage I/II), of
whom two had LONIPCs. Four had severe GVHD (stage III/
IV) and all of them had LONIPCs. All patients with moderate-
to-severe GVHD had at least skin and gastrointestinal
involvement. All four patients with severe GVHD died.
HRCT
A total of 67 HRCT scans were performed in 20 patients (1–
8 studies per patient). The patterns of abnormalities on HRCT
in the nine patients with LONIPCs are summarized in Table 2.
The pattern and the extension of CT findings were variable.
Interstitial thickening was shown in all nine patients. The
only patient with autologous BMT and abnormalities on
Fig. 5 Allogeneic BMT
patients with mild cGVHD and
good outcome. HRCT images
show both extensive lung in-
volvement with ground-glass
opacity (a) and interstitial
thickening (b black arrows), or
centrilobular nodules and
micronodules (c white arrow)
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HRCT had marked interstitial thickening (Fig. 1) in strict
spatial correlation with therapeutic radiation.
On the basis of HRCT it was impossible to subclassify
patients with LONIPCs (BO, interstitial pneumonia, DAD,
BOOP). None of the patients fulfilled the clinical and CT
definitions for BO. Three of four patients with GVHD had
bullae (Fig. 2) and unilateral pneumothorax (Fig. 2).
However, patients with GVHD did not show a specific
pattern of abnormalities on HRCT (Table 2). In the patient
with DAD, the pattern on HRCT, severe GVHD and poor
clinical outcome are in accordance with reports in the
literature [4, 16]. In this patient the lung abnormalities were
extensive (Fig. 3). Two patients were classified as having
BOOP on the basis of clinical and CT findings; lung
parenchyma involvement was extensive (Fig. 4). In the two
patients who had allogeneic BMT and mild GVHD, the
clinical course was satisfactory (Fig. 5).
Statistics
There was no statistically significant difference in the
incidence of LONIPCs between patients after one or
multiple BMTs (P=0.2), nor between patients receiving
TBI or chemotherapy only as the conditioning regimen (P=
0.26). There was no statistically significant association
between the presence of GVHD and a diagnosis of
LONIPCs on HRCT (P=0.16). However, there was a
significant association between abnormalities on HRCT
and severe GVHD (P=0.038; Table 3). All patients with
severe GVHD died. The association between severe GVHD
(stage III/IV) and death was significant (P=0.002; Table 4).
Discussion
The current longitudinal study is the first in the paediatric
literature to investigate the incidence of LONIPCs on
HRCT in allogeneic versus autologous BMT in order to
ascertain whether a correlation exists with GVHD [21]. The
incidence of LONIPCs was higher than that reported
previously (range 3–26%) [22–24]. This can be partially
explained by the relative homogeneity of the patients in our
series in contrast with other studies that included adults and
different conditioning regimens. LONIPCs are found
almost exclusively in patients with allogeneic rather than
autologous BMT [1, 13, 25]. In fact, the only patient (one
of eight) with abnormalities on HRCT after autologous
BMT had interstitial thickening following local radiation,
thus probably not directly related to the BMT.
The patients in the two groups were relatively homoge-
neous (Table 3). The only significant association was with
the presence of severe GVHD (P=0.038), confirming the
belief that the lung can be a target of GVHD [3]. The
spatial extension of abnormalities on HRCT was not
correlated with either GVHD or with clinical outcome. In
fact, the two patients with extensive ground-glass opacities
and consolidations were the only two without GVHD and
had a very good outcome. These two children had been
diagnosed with BOOP on the basis of HRCT and clinical
findings. Our study supports reports in the literature that
BOOP is not a manifestation of GVHD [26] and usually
has a good outcome. On the contrary, most patients with
abnormalities on HRCT associated with severe GVHD and
a poor outcome showed limited spatial extension (Fig. 2).
There was no correlation between a specific pattern and the
presence or severity of GVHD, or with the clinical outcome
in those with pulmonary pathology, although bullae and
pneumothorax tended to show an association with severe
GVHD (Table 2).
We investigated the possibility of subclassifying
LONIPCs into BO, BOOP and interstitial pneumonia
Table 3 Comparison between patients with LONIPCs and without
LONIPCs.
With LONIPCs Without LONIPCs P valuea
BMT type
Allogeneic 8 8 0.087
Autologous 1 7
No. of BMTs
Two 3 2 0.2
One 6 13
Donor
Nonrelated 6 4 0.3
Related 2 4
TBI
Yes 3 5 0.3
No 5 3
Cyclophosphamide
Yes 4 10 0.26
No 5 5
cGVHD
Yes 6 3 0.16
No 2 5
cGVHD grade
III/IV 4 0 0.038
0/I/II 4 8
a Fisher’s exact test
Table 4 Outcome in relation to cGVHD grade.
cGVHD grade Dead Alive P valuea
III/IV 4 0 0.002
0/I/II 1 11
a Fisher’s exact test
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according to the classification of Afessa et al. [5], which
could be important in predicting the clinical outcome. This
subclassification was not possible on the basis of HRCT
findings alone. However, HRCT findings combined with
clinical data and BAL results may be of real value in
narrowing the differential diagnosis. For instance, in our
series no patient fulfilled all the criteria for the diagnosis of
BO, probably because they were too young or their clinical
condition was too poor to perform accurate pulmonary
function tests [11]. The finding of bullae or pneumothorax
on HRCT is regarded as indirect evidence of BO or
interstitial pneumonia. All of the patients with bullae and
pneumothorax had GVHD and the clinical outcome was
unfavourable. Also, in the only patient with DAD, the
correct diagnosis resulted from the combination of clinical
data, BAL and HRCT findings. The association of DAD
with severe GVHD and poor clinical outcome is well
described in the literature [4, 16] and was also found in our
patient. All patients with severe GVHD died, verifying the
significant association between severe GVHD (stage III/IV)
and death (P=0.02).
The clinical symptoms of LONIPCs may be insidious at
the beginning of the disease, and routine radiological
examination may also be normal. Furthermore, in
LONIPCs, response to immunosuppressive therapy is
limited, the best outcome being preservation of remaining
lung function rather than significant improvement [14].
Since enhanced immunosuppression increases the risk of
infection, the utility of such therapy is questionable when
pulmonary dysfunction is chronic. Thus it is of the utmost
importance to perform HRCT early in order to suggest the
diagnosis of LONIPCs. Further prospective studies are
required to determine the role of HRCT in patients with
GVHD before the development of LONIPC-related respi-
ratory symptoms.
Conclusion
The significant association between HRCT abnormalities
and severe cGVHD (grades III/IV) suggests that LONIPCs
can be a pulmonary manifestation of the disease. The
prognosis seems to be related to the severity of GVHD and
not to the pattern or extension of HRCT abnormalities. The
accurate diagnosis of LONIPC subclasses is not possible on
the basis of HRCT alone. However, HRCT combined with
clinical data and BAL assists in narrowing the differential
diagnosis and establishing the prognosis.
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